Showing 7401-7410 of 8892 results for "".
- Research Reveals How Skin May Repair Itselfhttps://practicaldermatology.com/news/research-reveals-how-skin-may-repair-itself/2460755/Activation of two transcription factors may enhance a natural process of skin cell division, a desirable outcome in regenerative medicine, according to a study in Nucleic Acid Research. In normal conditions, one in every four cells isolated from the inner layer of the skin
- GEMME Webinar Series to Assess Impact of Essential Mask Wearing on Skinhttps://practicaldermatology.com/news/gemme-webinar-series-to-assess-impact-of-essential-mask-wearing-on-skin/2460754/Assessing the impact of essential mask wearing, the first of a series of four webinars from GEMME (Galderma Excellence Multichannel Medical Education) launches next month. “Under the mask: the consequences of essential mask wearing,” will stream Saturday, May 8, with Drs. Lu
- ASDSA Alerts Nation’s Governors to New Trend in Anti-transgender Legislationhttps://practicaldermatology.com/news/asdsa-alerts-nations-governors-to-new-trend-in-anti-transgender-legislation/2460749/The American Society for Dermatologic Surgery Association (ASDSA) sent a letter to all 50 state governors along with legislative leaders, alerting them to the increase in anti-transgender legislation that is proliferating in state legislatures across the country. After Arkansas be
- Expert Opinion: Fleshing Out the Role of Biosimilars in Dermatologyhttps://practicaldermatology.com/news/expert-opinion-fleshing-out-the-role-of-biosimilars-in-dermatology/2460742/Two new studies of biosimilars of tumor necrosis factor blockers that are used to treat a number of dermatologic conditions suggest that they are equivalent to their originator drugs, but there may be more involved in making the decision about switching to a biosimilar than lower cost.
- Dermatological Advocates Present Dr. Adam Friedman with Advocacy Leadership Awardhttps://practicaldermatology.com/news/dermatological-advocates-present-dr-adam-friedman-with-advocacy-leadership-award/2460738/The Derma Care Access Network (DCAN), a national non-profit coalition advocating for patient access to optimal dermatological care, is recognizing Adam Friedman, MD with its inaugural Advocacy Leadership Award for his work as a passionate advocate and
- Pediatric Dermatology Incomes Up; Demand Persists: Surveyhttps://practicaldermatology.com/news/pediatric-dermatology-incomes-up-demand-persists-survey/2460735/Median total compensation for pediatric dermatologists has increased 37 percent since 2014, results of The Society for Pediatric Dermatology’s (SPD) latest compensation report show. The
- Survey: Parents Extremely Worried About the Physical and Emotional Toll that Severe Acne Takes on Teenshttps://practicaldermatology.com/news/survey-parents-extremely-worried-about-the-physical-and-emotional-toll-that-severe-acne-takes-on-teens/2460734/Parents are very worried about the effects of severe acne on their teens, according to a new survey sponsored by Sun Pharma, in collaboration with the American Acne and Rosacea Society (AARS). The survey, which polled 250 parents of teenagers with severe nodular or cystic acne, sho
- Journey Medical to Acquire Dermira's Qbrexzahttps://practicaldermatology.com/news/journey-medical-to-acquire-dermiras-qbrexza/2460731/Journey Medical Corporation, a partner company of Fortress Biotech, Inc., has entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the US from Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company. The transaction is expected to close early in the secon
- Dermata Doses First Patient in Phase 1b Trial of Topical DMT310 for Mild-to-Moderate Psoriasishttps://practicaldermatology.com/news/dermata-doses-first-patient-in-phase-1b-trial-of-topical-dmt310-for-mild-to-moderate-psoriasis/2460726/Dermata Therapeutics, Inc. dosed its first patient in a Phase 1b trial of DMT310 for the treatment of mild-to-moderate psoriasis. DMT310 is currently being investigated to treat multiple inflammatory skin diseases. It consists of a once-weekly topical treatment with both mech
- NRS Launches Updated Version of "Understanding Rosacea" for Patientshttps://practicaldermatology.com/news/nrs-launches-updated-version-of-understanding-rosacea-for-patients/2460721/The National Rosacea Society has updated its most popular educational booklet. The new edition of “Understanding Rosacea” incorporates the updated standard classification and pathophysiology of rosacea, developed by a consensus committee and review panel of 28 rosacea experts worldwid